Emorivir Capsule 200 mg contains Molnupiravir, an oral antiviral medicine used for the treatment of mild to moderate COVID-19 in adults who are at risk of developing severe illness. Molnupiravir works by inhibiting the replication of the SARS-CoV-2 virus, helping to reduce viral load and limit disease progression when administered early in the course of infection. Emorivir Capsule offers a convenient oral treatment option, supporting outpatient management and reducing the risk of hospitalization when used as prescribed.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Active Ingredient and Mechanism of Action

Molnupiravir (200 mg)
Molnupiravir is a prodrug of a ribonucleoside analogue that is metabolized in the body to its active form. The active metabolite is incorporated into the viral RNA during replication, leading to the accumulation of errors in the viral genome. This process, known as lethal mutagenesis, prevents the virus from producing viable copies of itself. By disrupting viral replication, Molnupiravir helps control infection and supports the body’s immune response in clearing the virus.

Indications

Emorivir Capsule is indicated for:

• Treatment of mild to moderate COVID-19 infection in adults

• Patients with confirmed SARS-CoV-2 infection who are at increased risk of progressing to severe disease

• Use in non-hospitalized patients when treatment is initiated early after symptom onset

This medicine should be used according to national or local treatment guidelines and under the supervision of a healthcare professional.

Key Benefits

• Oral antiviral therapy for convenient outpatient use

• Helps reduce viral replication when taken early in infection

• May lower the risk of disease progression in high-risk patients

• Simple dosing regimen improves patient adherence

• Does not require intravenous administration

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Dosage and Administration

The recommended dosage is 800 mg (four 200 mg capsules) taken twice daily for 5 days, or as directed by a physician. Capsules should be swallowed whole with water and can be taken with or without food. Treatment should be started as soon as possible after diagnosis and within the recommended time frame from symptom onset.

Precautions and Warnings

• Not recommended for use during pregnancy due to potential risk to the fetus.

• Women of childbearing potential should use effective contraception during treatment.

• Use in breastfeeding women should be based on medical advice.

• Not approved for use in patients under 18 years of age.

• Emorivir Capsule should not be used for pre-exposure or post-exposure prophylaxis.

Possible Side Effects

Molnupiravir is generally well tolerated. Commonly reported side effects may include nausea, diarrhea, dizziness, headache, or mild gastrointestinal discomfort. Most adverse effects are mild and resolve without discontinuation of therapy.

Storage

Store in a cool, dry place below 30°C. Protect from light and moisture. Keep out of reach of children.